Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
ACAD
Strong BuyPremium GrowerACADIA Pharmaceuticals Inc. · Healthcare · United States · $5.0B · Avg Vol: $46M/d
COMPANY DESCRIPTION
ACADIA Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing therapies for central nervous system (CNS) disorders. Its flagship product, NUPLAZID (pimavanserin), addresses Parkinson's disease psychosis, providing a proprietary solution in a high-unmet-need area. ACADIA operates as a niche player targeting specific neurological conditions with advanced drug candidates and patent protection.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 517.2M | 726.4M | 957.8M | 1.1B | 27.5% | 1.1B | 1.3B | 1.4B | 15.6% |
| EPS | -1.34 | -0.37 | 1.37 | 2.32 | 69.3% | 2.23 | 1.68 | 2.49 | 3.6% |
| Shares | 162.1M | 164.7M | 166.7M | 170.3M | +5.1% | 172.3M | — | — | — |
| Debt | 62.0M | 57.2M | 52.0M | 52.2M | -5.6% | 73.9M | — | — | — |
| Equity | 400.4M | 431.8M | 732.8M | 1.2B | 45.3% | — | — | — | — |
| Op CF | -114.0M | 16.7M | 157.7M | 109.8M | 156.4% | 160.3M | — | — | — |
| Inv CF | 73.2M | 32.0M | -30.5M | -302.6M | — | — | — | — | — |
| Fin CF | 8.2M | 25.1M | 6.8M | 49.9M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ACAD are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| ACAD | ACADIA Pharmaceuticals Inc.(you) | $5.0B | 83 | Strong Buy |
| LGND | Ligand Pharmaceuticals Incorporated | $5.6B | 67 | Buy |
| TECH | Bio-Techne Corporation | $11.3B | 76 | Buy |
| KRYS | Krystal Biotech, Inc. | $10.4B | 74 | Buy |
| CORT | Corcept Therapeutics Incorporated | $12.3B | 71 | Buy |
| CAI | Caris Life Sciences, Inc. | $7.2B | 60 | Hold |
| HALO | Halozyme Therapeutics, Inc. | $12.0B | 95 | Strong Buy |
| TVTX | Travere Therapeutics, Inc. | $6.2B | 54 | Hold |
| HRMY | Harmony Biosciences Holdings, Inc. | $2.3B | 100 | Strong Buy |
| ABUS | Arbutus Biopharma Corporation | $1.0B | 84 | Strong Buy |
Peer medians: ROE -30.8% · P/E 27.1x · Gross margin 58.1%